Healthcare
AbbVie Inc.(ABBV)
Data coverage status · 7 need attention
Quote through 2026-08-05T13:30:00Z · Stale
Quote synced 2026-08-05T22:28:25.773298Z
Daily bars through 2026-08-03 · Stale
Daily bars synced 2026-08-04T18:42:49.589628Z
Fundamentals through 2025-12-31 · Stale
Fundamentals synced 2026-08-05T21:09:44.603401Z
Forecasts: Stale
Forecasts synced 2026-05-05T11:56:08.371548Z
Ownership through 2025-12-31 · Stale
Ownership synced 2026-08-05T21:09:44.603401Z
Short interest through 2025-12-31 · Stale
Short interest synced 2026-08-05T21:09:44.603401Z
News through 2026-05-19T10:01:28Z · Stale
News synced 2026-05-19T14:11:18.120035Z
Company profile: Delayed
Company profile synced 2026-05-06T21:57:03.437795Z
Regular-session price
Offline$246.20
+0.98% regular session
1Y Change
+22.64%
Window
Aug 5, 2025 → Aug 4, 2026
- Market Cap
- $368.20B
- P/E
- 101.5
- Trailing
- 52W Range
- $184.63 - $267.47
- Volume
- 5.09M
- 0.7x RVOL
Investment Snapshot
Valuation, growth, profitability, catalysts, and benchmark context.
1D
+1.0%
1M
-4.4%
6M
+12.2%
YTD
+6.2%
1Y
+22.6%
- Market Cap
- $368.20B
- NYSE
- P/E
- 101.5
- Trailing valuation
- Revenue Growth
- +8.6%
- TTM growth
- EPS Growth
- -1.4%
- TTM earnings growth
- Operating Margin
- 32.8%
- TTM profitability
- Forward P/E
- —
- Waiting on consensus EPS
- Next Earnings
- Oct 31, 2026
- In 87 days
- 52W Position
- 74%
- $184.63 - $267.47
- Volume
- 0.7x
- 5.09M shares latest
- Benchmark
- -0.18 pts
- vs SPY over 1Y
- Dividend
- 3.2%
- Last ex-date Apr 15, 2026
Coverage: 250 bars · Aug 5, 2025 → Aug 4, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
AbbVie Inc. (ABBV) is a Healthcare stock with listed on NYSE. The stock last traded around $246.20 and up 22.6% across the available one-year price window (Aug 5, 2025 → Aug 4, 2026). Baseline metrics include revenue growth of +8.6%, EPS growth of -1.4%, a dividend yield of 3.2%. What stands out right now is revenue +8.6%, EPS -1.4%, free cash flow -0.1% with operating margin 32.8% and ROIC 10.6%. The dividend matters to the case here, with a current yield around 3.2%. Valuation already assumes a fairly strong business story at P/E 101.5 and price/sales 5.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ABBV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+8.6% vs +6.2% peer median
Operating Margin
Above sector median
+32.8% vs +10.1% peer median
P/E
Above sector median
101.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
Q3 2026 was reported on Jul 31, 2026 with an EPS surprise of +1.1%.
The operating picture looks softer than before
Revenue is at +8.6% and EPS is at -1.4%, with operating margin around 32.8%.
The next real check-in already has a date
The next earnings event is scheduled for Oct 31, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged +4.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Delta | 1D | 5D | 20D |
|---|---|---|---|---|
Q3 2026 Jul 31, 2026 | +1.1% | -2.3% | -- | -- |
Q2 2026 Apr 28, 2026 | +3.1% | +3.1% | +4.3% | +9.0% |
Benchmark Edge
ABBV vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
Mixed setup vs SPY
ABBV is 0.18 pts behind over the shared 1Y window.
ABBV had 10.10 pts deeper max drawdown than SPY.
ABBV beat SPY in 1 of 2 calendar years shown and trailed in 1.
ABBV
+22.64%
Normalized return
SPY
+22.83%
S&P 500
Excess Return
-0.18 pts
Relative to SPY
ABBV Max Drawdown
-19.23%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ABBV and SPY.
| Year | ABBV | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +6.19% | +12.67% | -6.48 pts | SPY |
| 2025 | +15.71% | +9.40% | +6.31 pts | ABBV |
Company Overview
AbbVie Inc.
New York Stock Exchange
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
- Leadership
- Robert A. Michael
- IPO Date
- Jan 2, 2013
- Employees
- 55.0k
- Street Address
- 1 North Waukegan Road
- Mailing
- North Chicago, IL, 60064-6400
- Region
- North Chicago, IL, US
- Reporting Currency
- USD
- Investor Line
- 847 932 7900
- Last Updated
- May 6, 2026
Statistics & Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 101.5
- EV/EBITDA
- 24.0
- Price/Sales
- 5.9
- Price/Book
- N/MNon-positive book value
Growth
- Revenue
- +8.6%
- EPS
- -1.4%
- Free Cash Flow
- -0.1%
Profitability
- Gross Margin
- 70.2%
- Operating Margin
- 32.8%
- Net Margin
- 6.9%
- ROE
- -311.4%
- ROIC
- 10.6%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.21
Ownership & Float
- Float
- 1.76B
- Short Interest
- 1.4%
- Insider Owned
- 0.1%
- Institutional Owned
- 76.9%
Earnings Reports
Latest News
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.